XIPERE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xipere, and when can generic versions of Xipere launch?
Xipere is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are three patents protecting this drug.
This drug has eighty-one patent family members in eighteen countries.
The generic ingredient in XIPERE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xipere
A generic version of XIPERE was approved as triamcinolone acetonide by TARO on October 1st, 1986.
Summary for XIPERE
International Patents: | 81 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 83 |
Patent Applications: | 4,203 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for XIPERE |
What excipients (inactive ingredients) are in XIPERE? | XIPERE excipients list |
DailyMed Link: | XIPERE at DailyMed |
Pharmacology for XIPERE
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for XIPERE
US Patents and Regulatory Information for XIPERE
XIPERE is protected by three US patents and one FDA Regulatory Exclusivity.
Patents protecting XIPERE
Methods and devices for drug delivery to ocular tissue using microneedle
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS
Methods and devices for the treatment of ocular diseases in human subjects
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS
Apparatus and methods for ocular injection
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting XIPERE
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XIPERE
See the table below for patents covering XIPERE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Africa | 201400616 | METHODS AND DEVICES FOR DRUG DELIVERY TO OCULAR TISSUE USING MICRONEEDLE | ⤷ Try a Trial |
Australia | 2015230874 | METHODS AND DEVICES FOR DRUG DELIVERY TO OCULAR TISSUE USING MICRONEEDLE | ⤷ Try a Trial |
Japan | 6613342 | ⤷ Try a Trial | |
Japan | 2020014938 | 眼球注射の装置および方法 (EYEBALL INJECTION DEVICE AND METHOD) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |